amikacin
Antiinfectives for systemic use (J01)Antiinfectives for systemic use (J01) compound in Blackmores Institute's portfolio.
pharma · Peripheral Artery Disease · Muscle-Invasive Bladder Carcinoma
Blackmores Institute
Blackmores Limited
Blackmores Institute drug portfolio — 24 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
20 Jubilee Ave, Warriewood, New South Wales 2102, AU HQ
2012 Founded
27 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- 20 Jubilee Ave, Warriewood, New South Wales 2102, AU
- Founded
- 2012
- Employees
- 27
- Programs
- 17
- Drugs
- 24
- Patents
- 38
Blackmores Institute pipeline
Portfolio lens on 24 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Blackmores Institute drug portfolio — 24 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
azathioprine
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
US regulatory status: approved. Molecular target: Amidophosphoribosyltransferase.
- Target
- Amidophosphoribosyltransferase
- Mechanism
- Amidophosphoribosyltransferase inhibitor
-
bupivacaine
Nervous system (N01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
US regulatory status: approved.
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
ibandronic acid
Musculo-skeletal system (M05)Musculo-skeletal system (M05) compound in Blackmores Institute's portfolio. Mechanism: Farnesyl diphosphate synthase inhibitor.
- Mechanism
- Farnesyl diphosphate synthase inhibitor
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
levodopa
Nervous system (N04)US regulatory status: approved. Molecular target: D(3) dopamine receptor.
- Target
- D(3) dopamine receptor
- Mechanism
- Dopamine D3 receptor agonist
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
Development asset linked to Blackmores Institute in public FDA and regional records.
-
sirolimus
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
US regulatory status: approved.
-
temozolomide
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Blackmores Institute in public FDA and regional records.